BMS 986156
Alternative Names: BMS-986156Latest Information Update: 10 Oct 2022
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; TNFRSF18 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 10 Oct 2022 BMS 986156 is still in phase I trials for Solid tumours in USA (NCT03335540)
- 28 Mar 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV, Injection)
- 16 Dec 2020 Bristol-Myers Squibb completes a phase I/II trial in Solid tumours in Australia, Belgium, Canada, France, Germany, Italy, the Netherlands, Spain, Switzerland and the USA (NCT02598960)